Corcept's Ovarian Cancer Drug Shows Promising Results in Phase 3 Trial

San Francisco, Monday, 31 March 2025.
Corcept Therapeutics’ relacorilant reduces disease progression by 30% in platinum-resistant ovarian cancer, improving survival. Shares surged 77% after announcing results on March 30, 2025.